CBRNE – Nerve Agents, Binary – GB2, VX2
No Results
No Results
processing….
In the 1950s, the US Army began to consider the development of binary nerve agent weapons to provide increased safety during storage and handling. At that time, unitary nerve agent weapons were the only ones in existence. In unitary agents, the chemicals were produced in a plant, loaded into the missile, and stored in a ready-to-use fashion. This method has several drawbacks. Because the munitions are highly toxic, storage, handling, and deployment need to be performed with extreme caution. Unitary weapons therefore pose a considerable risk to the ground crew and others who work with the chemicals. The agents in the active form are also highly corrosive; thus, extended storage times increase the risk of a leak.
The concept of binary weapons began to develop in the 1960s. Binary weapons involve nontoxic precursors that can be loaded in munitions. Once deployed, the precursors mix and develop the nerve agent. Below is a timeline (adapted from Sidell, 1997; Smart, 1996; and Organisation for the Prohibition of Chemical Weapons) that highlights important dates in the development of binary technology:
1960s: The BIGEYE, a 500-lb bomb with binary technology, is developed for the US Navy. Its production was halted in 1990.
September 16, 1969: A 155-mm projectile filled with sarin binary reagents is test fired at Dugway Proving Ground.
1976: The US Army standardizes the M687 Binary GB2 155-mm projectile.
1976: The US Congress passes the Department of Defense Appropriation Authorization Act, which restricts the development and production of binary weapons unless the President certifies to the Congress that such production is essential to the national interest.
1985: Public Law 99-145 (US Congress) authorizes production of chemical weapons.
1987: President Reagan certifies to US Congress the need for chemical weapons.
December 16, 1987: M687 binary projectile starts production at Pine Bluff.
June 1, 1990: The United States and the Soviet Union sign the bilateral chemical weapons destruction agreement.
1991: Iraq declares to the United Nations Special Commission (UNSCOM) a different binary munition concept. The projectiles would contain only 1 canister with a single precursor. Before use, the munition would be opened, and the second precursor would be added. The chemical reaction then starts just prior to the munition release.
A binary projectile contains 2 separate, hermetically sealed, plastic-lined containers fitted, one behind the other, in the body of the projectile. In the sarin (GB) binary weapon, the forward canister contains methylphosphonic difluoride (DF). The rear canister contains an isopropyl alcohol and isopropylamine solution (OPA). Only the forward canister is in the munition prior to use. Before the weapon is fired, the rear canister is added and the fuse is placed. The force of launch causes the canisters to break, which produces GB within the projectile.
Known binary agents include the following:
GB binary (sarin, GB2): DF is located in 1 canister, while OPA is in a second canister. The isopropyl amine binds to the hydrogen fluoride generated during the chemical reaction. After deployment of the weapon, the 2 canisters rupture and the chemical mixture produces GB.
GD binary (soman, GD2): DF is located in 1 canister, while a mixture of pinacolyl alcohol and an amine is in a second canister. After deployment of the weapon, the 2 canisters rupture and the chemical mixture produces GD.
VX binary (VX2): O-Ethyl O-2-diisopropylaminoethyl methylphosphonite (QL) is in 1 canister. The other canister contains elemental sulfur. When the weapon is fired, the canisters rupture and the chemical mixture produces VX.
Novichok agent (“Newcomer”): a series of nerve agents developed by the Soviet Union in the 1980s and 1990s, all in the “third generation nerve agent” category. Some of these agents (Novichok-5, Novichok-7) are binary agents.
The final product of the weapon is of the same chemical structure as the original nerve agent. The term binary refers only to the storage and deployment method used, not to the chemical structure of the substance. This article discusses management of chemical nerve agents in general; the reader can also refer to CBRNE – Nerve Agents, G-series – Tabun, Sarin, Soman and CBRNE – Nerve Agents, V-series – Ve, Vg, Vm, Vx for more detailed information on each particular agent.
Nerve agents comprise various compounds that have the capacity to inactivate the enzyme acetylcholinesterase (AChE). They are generally divided into 2 families, the G agents and the V agents (VX is the prototype of V agents). The Germans developed the G agents (ie, tabun [GA], sarin [GB], soman [GD]) during World War II. The G agents are highly volatile liquids that pose mainly an inhalation hazard. The V agents were developed later in the United Kingdom. They are approximately 10 times more toxic than GB. The V agents are less volatile and have an oily consistency; thus, they mainly pose a contact hazard. They are considered “persistent agents,” which means that they can remain viable on surfaces for long periods of time.
Nerve agents bind to AChE much more potently than organophosphate and carbamate insecticides do. AChE is the enzyme that mediates the degradation of acetylcholine (ACh). ACh is an important neurotransmitter of the peripheral and central nervous systems. Acetylcholine activates 2 types of receptors, muscarinic and nicotinic. Nicotinic ACh receptors are found at the skeletal muscle and at the autonomic ganglia. The muscarinic receptors are found mainly in the postganglionic parasympathetic fibers and the brain. Therefore, nerve agent toxicity is manifested as excessive cholinergic transmission at both types of receptor sites.
ACh is released when an electrical impulse reaches the presynaptic neuron. The neurotransmitter travels across the synaptic cleft and reaches the postsynaptic membrane. There, it binds to its receptor (muscarinic or nicotinic). This interaction leads to activation of the ACh receptor and signal transmission in the postsynaptic side of the cleft. Normally, after this interaction between ACh and its receptor, ACh is rapidly degraded (hydrolyzed) into choline and acetic acid by AChE. This renders the ACh receptor active again. Choline undergoes reuptake into the presynaptic cell and is used to regenerate ACh.
Nerve agents act by inhibiting the hydrolysis of ACh by AChE. They bind to the active site of AChE, rendering it incapable of deactivating ACh. Any ACh that is not hydrolyzed can continue to interact with the postsynaptic receptor, which results in persistent and uncontrolled stimulation of that receptor. After persistent activation of the receptor, fatigue results. This is the same principle exhibited by the depolarizing neuromuscular blocker succinylcholine. The clinical effects of nerve agents are the result of this persistent stimulation and subsequent fatigue at the ACh receptor.
In an initial step, the enzyme becomes inactivated, but not permanently. Some degree of reactivation of the AChE enzyme occurs in this initial phase, but the process is slow. An additional reaction between AChE and the nerve agent makes their interaction irreversible, a phenomenon known as “aging.” For the clinical effect to be reversed after aging occurs, new AChE enzyme must be produced. This irreversible bond is one difference between organophosphate compounds (including nerve agents) and carbamates, which bind reversibly to AChE. This concept is also used for pretreatment of military personnel with the carbamate pyridostigmine.
The typical aging half-lives for the different nerve agents are listed as follows:
GA (tabun) – 14 hours
GB (sarin) – 5 hours
GD (soman) – 2-6 minutes
VX – 48 hours
United States
No instances of binary nerve agent use or intentional release have been reported in the United States.
International
Although G agents were synthesized during World War II, no evidence exists that they ever were used in actual combat. Evidence is available that they were tested in concentration camps, however. The only known instance in which nerve agents were used in combat was during the Iran/Iraq war. The Iraqis also allegedly used them against the Kurds, most infamously at the town of Halabja in 1987. GB was used in Matsumoto, Japan, in 1994, and in the Tokyo subway attack in 1995, in the only two reported terrorist uses of sarin.
The threat of the use of nerve agents in terrorism is pervasive. Countries that are in political turmoil are at a higher risk for terrorist events. An unknown number of countries and terrorist groups may possess or have the capacity to manufacture nerve agents.
No instances have been reported in which the agents have been released in the form of binary weapons.
Toxicity of nerve agents is measured in two forms, median lethal concentration (LCt50) and median lethal dose (LD50). The LD50 is the lethal dose to 50% of exposed population, and refers to liquid or solid exposures. LCt50 refers to the inhalational toxicity of the vapor form of a volatile agent. Ct refers to the concentration of the vapor or aerosol in the air (measured as mg/m3) multiplied by the time the individual is exposed (measured in minutes). The LCt50 thus refers to the vapor exposure necessary to cause death in 50% of an exposed population. With an LCt50 of 10 mgXmin/m3, VX is the most toxic of the nerve agents (see Table 1).
Table 1. Toxicity of Nerve Agents (Open Table in a new window)
Agent
Chemical Name
LCt50, mgXmin/m3
LD50,
mg
GA
Ethyl N -dimethylphosphoramidocyanidate
400
1000
GB
Isopropyl methylphosphonofluoridate
100
1700
GD
Pinacolyl methylphosphonofluoridate
50
100
VX
O-Ethyl S-2-diisopropylaminoethyl methylphosphonothioate
10
10
Sensitivity to nerve agents varies with the individual, but no studies have addressed differential susceptibility based on race.
Everyone is at risk of being a target of terrorism. Military personnel are theoretically at increased risk; however, no gender predilection exists. No studies have been performed looking at differential susceptibility to nerve agents according to gender.
Everyone is at risk of being a target of terrorism. Military personnel are theoretically at increased risk; however, no predilection based on age exists.
Some limited evidence exists that children may be more susceptible than adults to the effects of organophosphate insecticides. In animal studies, lethal doses for immature and juvenile rats were 10% and 33%, respectively, of the lethal dose for adult rats.
Marrs TC, Maynard RL, Sidell FR. Chemical Warfare Agents: Toxicology and Treatment. New York, NY: John Wiley & Sons; 1996.
Thors L, Lindberg S, Johansson S, Koch B, Koch M, Hägglund L, et al. RSDL decontamination of human skin contaminated with the nerve agent VX. Toxicol Lett. 2017 Mar 5. 269:47-54. [Medline].
Zhu H, Jung EC, Phuong C, Hui X, Maibach H. Effects of soap-water wash on human epidermal penetration. J Appl Toxicol. 2016 Aug. 36 (8):997-1002. [Medline].
Worek F, Thiermann H, Wille T. Oximes in organophosphate poisoning: 60 years of hope and despair. Chem Biol Interact. 2016 Nov 25. 259 (Pt B):93-98. [Medline].
Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway sarin attack: disaster management, Part 1: Community emergency response. Acad Emerg Med. 1998 Jun. 5(6):613-7. [Medline].
Sidell FR. Clinical considerations in nerve agent intoxications. Chemical Warfare Agents. San Diego, CA: Academic Press, Inc; 1992.
Baker MD. Antidotes for nerve agent poisoning: should we differentiate children from adults?. Curr Opin Pediatr. 2007 Apr. 19(2):211-5. [Medline].
Borbely AA, Tunod U, Hopft W. Studies on the protective action of atropine and obidoxime against sarin poisoning in mice. Cholinergic Mechanisms. Philadelphia, Pa: Lippincott-Raven; 1975.
Christensen MK, Crethull P, Crook JW, et al. Resuscitation of dogs poisoned by inhalation of the nerve gas GB. Mil Med. 1956 Dec. 119(6):377-86. [Medline].
Corvino TF, Nahata MC, Angelos MG, Tschampel MM, Morosco RS, Zerkle J. Availability, stability, and sterility of pralidoxime for mass casualty use. Ann Emerg Med. 2006 Mar. 47(3):272-7. [Medline].
Department of the Army. Binary chemical munitions program. Programmatic Environmental Impact Statement ARCSL-EIS-8101. 1981:1-7.
Foltin G, Tunik M, Curran J, Marshall L, Bove J, van Amerongen R. Pediatric nerve agent poisoning: medical and operational considerations for emergency medical services in a large American city. Pediatr Emerg Care. 2006 Apr. 22(4):239-44. [Medline].
Freeman G, Marzulli FN, Craig AB. The toxicity of liquid GB applied to the skin of man. MLRR. 1954:217.
Grob D, Harvey AM. The effects and treatment of nerve gas poisoning. Am J Med. 1953 Jan. 14(1):52-63. [Medline].
Harris LW, Fleisher JH, Clark J, Cliff WJ. Dealkylation and loss of capacity for reactivation of cholinesterase inhibited by sarin. Science. 1966 Oct 21. 154(747):404-7. [Medline].
Henderson JD, Higgins RJ, Dacre JC, Wilson BW. Neurotoxicity of acute and repeated treatments of tabun, paraoxon, diisopropyl fluorophosphate and isofenphos to the hen. Toxicology. 1992. 72(2):117-29. [Medline].
Inns RH, Leadbeater L. The efficacy of bispyridinium derivatives in the treatment of organophosphonate poisoning in the guinea-pig. J Pharm Pharmacol. 1983 Jul. 35(7):427-33. [Medline].
Keim ME, Pesik N, Twum-Danso NA. Lack of hospital preparedness for chemical terrorism in a major US city: 1996-2000. Prehospital Disaster Med. 2003 Jul-Sep. 18(3):193-9. [Medline].
Kunkel AM, O’Leary JF, Jones AH. Atropine-induced ventricular fibrillation during cyanosis caused by organophosphorous poisoning. Edgewood Arsenal Technical Report 4711. 1973.
Lallement G, Clarencon D, Masqueliez C, et al. Nerve agent poisoning in primates: antilethal, anti-epileptic and neuroprotective effects of GK-11. Arch Toxicol. 1998. 72(2):84-92. [Medline].
LeBlanc FN, Benson BE, Gilg AD. A severe organophosphate poisoning requiring the use of an atropine drip. J Toxicol Clin Toxicol. 1986. 24(1):69-76. [Medline].
Lee EC. Clinical manifestations of sarin nerve gas exposure. JAMA. 2003 Aug 6. 290(5):659-62. [Medline].
Marrs TC. The role of diazepam in the treatment of nerve agent poisoning in a civilian population. Toxicol Rev. 2004. 23(3):145-57. [Medline].
Marrs TC. Toxicology of oximes used in treatment of organophosphate poisoning. Adverse Drug React Toxicol Rev. 1991. 10(1):61-73. [Medline].
McDonough JH, McLeod CG, Nipwoda MT. Direct microinjection of soman or VX into the amygdala produces repetitive limbic convulsions and neuropathology. Brain Res. 1987 Dec 1. 435(1-2):123-37. [Medline].
Mitretek Systems. Binary Chemical Weapons. Noblis. Available at http://www.noblis.org/BinaryChemicalWeapons.htm.
Newmark J. Nerve agents: pathophysiology and treatment of poisoning. Semin Neurol. 2004 Jun. 24(2):185-96. [Medline].
Nozaki H, Aikawa N, Fujishima S, et al. A case of VX poisoning and the difference from sarin. Lancet. 1995 Sep 9. 346(8976):698-9. [Medline].
Nozaki H, Hori S, Shinozawa Y, et al. Secondary exposure of medical staff to sarin vapor in the emergency room. Intensive Care Med. 1995 Dec. 21(12):1032-5. [Medline].
Okudera H. Clinical features on nerve gas terrorism in Matsumoto. J Clin Neurosci. 2002 Jan. 9(1):17-21. [Medline].
Parker RM, Crowell JA, Bucci TJ. Negative delayed neuropathy study in chickens after treatment with isopropyl methylphosphonofluoridate (sarin, type 1). Toxicol. 1988. 8:248.
Rickett DL, Glenn JF, Beers ET. Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology. 1986. 7(1):225-36. [Medline].
Robineau P, Guittin P. Effects of an organophosphorous compound on cardiac rhythm and haemodynamics in anaesthetized and conscious beagle dogs. Toxicol Lett. 1987 Jun. 37(1):95-102. [Medline].
Rotenberg JS. Diagnosis and management of nerve agent exposure. Pediatr Ann. 2003 Apr. 32(4):242-50. [Medline].
Schier JG, Ravikumar PR, Nelson LS. Preparing for chemical terrorism: stability of injectable atropine sulfate. Acad Emerg Med. 2004 Apr. 11(4):329-34. [Medline].
Secretariat of the Organisation for the Prohibition of Chemical Weapons. Nerve Agents. ICA Division, OPCW. Organisation for the Prohibition of Chemical Weapons. Available at http://www.opcw.org/.
Sidell FR. Nerve agents. Textbook of Military Medicine. Washington, DC: TMM Publications; 1997.
Sidell FR, Groff WA. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol. 1974 Feb. 27(2):241-52. [Medline].
Sim VM. Variability of different intact human skin sites to the penetration of VX. CRDL Report 3122. 1962.
Sim VM, Stubbs JL. VX percutaneous studies in man. CRDL Report 3015. 1960.
Smart JK. History of Chemical and Biological Warfare Fact Sheets. 1996.
Somani SM, Solana RP, Dube SN. Toxicodynamics of nerve agents. Chemical Warfare Agents. San Diego, CA: Academic Press Inc; 1992.
Thiermann H, Szinicz L, Eyer P, Felgenhauer N, Zilker T, Worek F. Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning. Toxicology. 2007 Apr 20. 233(1-3):145-54. [Medline].
Tokuda Y, Kikuchi M, Takahashi O, Stein GH. Prehospital management of sarin nerve gas terrorism in urban settings: 10 years of progress after the Tokyo subway sarin attack. Resuscitation. 2006 Feb. 68(2):193-202. [Medline].
Ward FP. Construction and Operation of a 155-mm M687 GB2 Binary Production Facility at Pine Buff Arsenal, Jefferson County, Arkansas. Environmental Assessment ARCSL-EA-8101. 1981:3-7.
Wills JH, DeArmon IA. A statistical study of the Adamek report. Medical Laboratory Special Report 54. AD045106.
Worek F, Eyer P, Aurbek N, Szinicz L, Thiermann H. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol Appl Pharmacol. 2007 Mar. 219(2-3):226-34. [Medline].
Wright PG. An analysis of the central and peripheral components of respiratory failure produced by anticholinesterase poisoning in the rabbit. J Physiol. 1954 Oct 28. 126(1):52-70. [Medline].
Young D. CDC rolls out nerve-agent antidote program. Am J Health Syst Pharm. 2004 Sep 15. 61(18):1866-8, 1875. [Medline].
Agent
Chemical Name
LCt50, mgXmin/m3
LD50,
mg
GA
Ethyl N -dimethylphosphoramidocyanidate
400
1000
GB
Isopropyl methylphosphonofluoridate
100
1700
GD
Pinacolyl methylphosphonofluoridate
50
100
VX
O-Ethyl S-2-diisopropylaminoethyl methylphosphonothioate
10
10
Severity of Exposure
Signs and Symptoms – Liquid*
Signs and Symptoms – Vapor†
Minimal
Localized sweating at site
Localized fasciculations at site
Miosis
Rhinorrhea
Slight dyspnea
Moderate
Above-mentioned symptoms and the following:
Nausea, vomiting, and diarrhea
Generalized weakness
Above-mentioned symptoms and the following:
Moderate-to-marked dyspnea
(bronchorrhea and/or bronchoconstriction)
Severe
Above-mentioned symptoms and the following:
Loss of consciousness
Seizures
Generalized fasciculations
Flaccid paralysis and apnea
Above-mentioned symptoms and the following:
Loss of consciousness
Seizures
Generalized fasciculations
Flaccid paralysis and apnea
* Onset possibly delayed
† Rapid onset of symptoms
Drug
Dose (Adult)
Route
Indications
Contraindications
Atropine
2 mg q5-10min prn
Note: The MARK 1 kit contains 2 mg of atropine.
IV/IM/ETT
Excessive muscarinic symptoms
Relative: IV route in hypoxia has been associated with ventricular fibrillation.
Pralidoxime chloride (Protopam, 2-PAM)
15-25 mg/kg over 20 min; can be repeated after 1 h
Note: The MARK 1 kit contains 600 mg of pralidoxime.
IV/IM
Symptomatic nerve agent poisoning
Rapid infusion may result in hypertension; may worsen symptoms in carbamate poisoning
Diazepam (Valium)
2-5 mg IV
10 mg IM
IV/IM
Moderate or severe signs of poisoning, seizures
None
*Adapted from Sidell, 1992. [6]
Severity/Route of Exposure
Atropine (Adult Dose)
Pralidoxime
Diazepam
Other
Suspected
No
No
No
Decontamination and 18-h observation for liquid exposures
Mild
2 mg for severe
rhinorrhea or
dyspnea; may be
repeated
Administer if dyspnea
is not improving
or if GI
symptoms occur
No
Decontamination and 18-h observation for liquid exposures; oxygen
Moderate
6 mg; may need to repeat
Administer with atropine
Administer even in absence of seizures
Decontamination; oxygen
Severe
Start with 6 mg; may need to repeat
Administer with atropine; should repeat once or twice
Administer even in absence of seizures
Airway, breathing, and circulation; decontamination
*Adapted from Sidell, 1992. [6]
Larissa I Velez-Daubon, MD Professor, Program Director, Department of Surgery, Division of Emergency Medicine, University of Texas Southwestern Medical School, Parkland Memorial Hospital; Staff Toxicologist, Department of Surgery, Division of Emergency Medicine, North Texas Poison Center, Parkland Memorial Hospital
Larissa I Velez-Daubon, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Medical Toxicology, Society for Academic Emergency Medicine, American College of Emergency Physicians
Disclosure: Nothing to disclose.
Fernando L Benitez, MD Assistant Medical Director, Dallas Metropolitan BioTel (EMS) System; Associate Professor in Emergency Medicine, Department of Surgery, Division of Emergency Medicine, University of Texas Southwestern Medical Center and Parkland Health and Hospital
Fernando L Benitez, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, National Association of EMS Physicians
Disclosure: Nothing to disclose.
Daniel C Keyes, MD, MPH Associate Chair, Academic Affairs, Department of Emergency Medicine, St Joseph Mercy Hospital; Clinical Faculty, Emergency Medicine Residency, University of Michigan Medical School; Clinical Associate Professor, Department of Surgery, Division of Emergency Medicine and Toxicology, University of Texas Southwestern School of Medicine
Daniel C Keyes, MD, MPH is a member of the following medical societies: American College of Emergency Physicians, American College of Medical Toxicology, American College of Occupational and Environmental Medicine, American College of Physicians-American Society of Internal Medicine
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Duane C Caneva, MD, MSc Senior Medical Advisor to Customs and Border Protection, Department of Homeland Security (DHS) Office of Health Affairs; Federal Co-Chair, Health, Medical, Responder Safety Subgroup, Interagency Board (IAB)
Disclosure: Nothing to disclose.
Fred Henretig, MD Director, Section of Clinical Toxicology, Professor, Medical Director, Delaware Valley Regional Poison Control Center, Departments of Emergency Medicine and Pediatrics, University of Pennsylvania School of Medicine, Children’s Hospital
Disclosure: Nothing to disclose.
CBRNE – Nerve Agents, Binary – GB2, VX2
Research & References of CBRNE – Nerve Agents, Binary – GB2, VX2|A&C Accounting And Tax Services
Source
0 Comments